GSK plc (GSK)
NYSE · London, United Kingdom · Founded 1715 · CEO Luke Miels
Valuation summary
$75.48 fair value versus $47.82 in the market, a difference of +57.8%. Rated Strong Buy.
| Fair value per share | $75.48 |
| Current share price | $47.82 |
| Upside / downside | +57.8% |
| Bear case | $47.33 |
| Bull case | $115.55 |
| Discount rate (WACC) | 8.4% |
| Terminal growth | 2.20% |
| Market capitalisation | $75B |
| EV / Sales | 2.9x |
About GSK plc
Traces to a London apothecary founded in 1715, with the modern company formed by the 2000 GlaxoWellcome and SmithKline Beecham merger. Emma Walmsley, CEO from 2017, separated consumer health as Haleon in 2022; Luke Miels, previously chief commercial officer, succeeded her as chief executive on 1 January 2026. GSK now focuses on vaccines, HIV through its ViiV stake, and specialty medicines. US-listed as an ADR.
Investment case
- Shingrix is the leading shingles vaccine with a large under-penetrated eligible population.
- The HIV franchise generates substantial and durable cash flow.
- One of the higher dividend yields in large-cap pharmaceuticals.
Key risks
- Zantac litigation created years of overhang, and legal risk in pharma rarely fully clears.
- The oncology pipeline still lags larger peers, although Jemperli's FDA priority review in rectal cancer and the September 2026 Chimagen myeloma deal show it is being rebuilt.
- Vaccine demand proved more cyclical post-pandemic than expected.
Recent developments
- 2026-10-28 · Q3 sales up 5% to GBP8.9bn as specialty medicines grow 15% while vaccines soften; 2026 guidance reaffirmed source
- 2026-10-06 · ViiV's long-acting Cabenuva beat daily oral therapy on viral suppression at six months in people with viremia in the Phase IIIb CROWN trial. source
- 2026-09-15 · GSK agreed to acquire a trispecific T cell-engager for multiple myeloma from Chimagen Biosciences for up to $750m including milestones. source
- 2026-09-01 · GSK will advance its mRNA seasonal flu vaccine candidate to Phase III after positive Phase II data. source
Revenue by segment
| Specialty Medicines | 40% |
| Vaccines | 33% |
| General Medicines | 27% |
Five-year forecast
| Revenue | Free cash flow | |
|---|---|---|
| Year 1 | $34.7B | $8.3B |
| Year 2 | $36.2B | $8.4B |
| Year 3 | $37.8B | $8.6B |
| Year 4 | $39.4B | $8.8B |
| Year 5 | $41.1B | $8.9B |
What the street says
A value case in European pharma, now under Luke Miels, who became chief executive on 1 January 2026. Pipeline news flow between August and October 2026 has been positive, including a Phase III start for an mRNA flu vaccine and a CROWN trial win for long-acting HIV therapy Cabenuva. Vaccine growth and pipeline delivery remain the recurring debates.
Comparable companies: TAK · PFE · ZTS · BMY · BIIB · TEVA · DHR · NVO
Open the interactive model, price chart and sensitivity grid →